国际肺癌筛查试验的经验教训:高危人群应通过筛查实现早期发现
本文综述了已发表肺癌筛查试验的近期临床进展,指出低剂量CT肺癌筛查已获广泛接受,许多地区基于高质量随机对照试验证据提供或计划提供人群筛查。优化实施对确保高参与率和质量保证至关重要,良好执行的筛查项目可与晚期肺癌靶向及免疫治疗进展互补,并讨论了亚太地区有效实施筛查项目的促进与障碍因素。
要点
- 低剂量CT肺癌筛查已获广泛接受,多地基于随机对照试验证据推行人群筛查。
- 优化实施是确保高参与率和质量保证、实现模型预测获益的关键。
- 筛查项目可与晚期肺癌分子靶向及免疫治疗进展互补,降低肺癌负担。
核心结论
- 低剂量CT肺癌筛查已获广泛接受,许多地区基于高质量随机对照试验证据提供或计划提供人群筛查。
研究设计与样本
- 本文为综述,描述已发表肺癌筛查试验的近期临床进展,并讨论全球尤其是亚太地区实施筛查项目的促进与障碍因素。
主要发现
- 优化实施对确保足够高参与率和高效质量保证的肺癌筛查项目至关重要,以实现模型和卫生技术评估预测的获益。
- 良好执行的肺癌筛查项目可与晚期肺癌引入分子靶向药物和免疫检查点抑制剂已实现的肺癌负担降低形成互补。
临床怎么用
- 临床应关注肺癌筛查项目的优化实施,以提高参与率和质量保证,并与晚期肺癌治疗进展形成互补。
- 在亚太地区实施肺癌筛查项目时需考虑本地区常见的促进与障碍因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the modern era, the role of lung cancer screening by low dose computed tomography (CT) is now broadly accepted, with many jurisdictions offering or intending to offer population-based screening based on high quality randomised controlled trial (RCT) evidence. Optimal implementation will be crucial to ensure sufficiently high participation rates in efficient quality assured lung cancer screening programmes (LCSPs) to achieve the gains predicted by modelling and health technology assessments. Performed well, LCSPs can be anticipated to complement the reduction in lung cancer burden already realised from the introduction of molecularly targeted agents and immune checkpoint inhibitors for advanced stage lung cancer. In this review, we will describe the recent clinical developments from published trials to highlight contemporaneous lung cancer screening (LCS) issues and discuss potential enablers and barriers to the effective implementation of LCSP commonly encountered across the world, particularly from the viewpoint of the Asia Pacific region and peoples.
引用
- Stone E, Marshall H, Yang PC, et al. Lessons Learned From International Lung Cancer Screening Trials; People at Risk Deserve Screening for Early Detection. Respirology. 2025. PMID: 40813230. doi:10.1111/resp.70097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。